| The genomic landscape of early stage ovarian high grade serous carcinoma Z Cheng, H Mirza, DP Ennis, P Smith, LM Gavarró, C Sokota, G Giannone, ... Clinical Cancer Research 28 (13), 2911–2922, 2022 | 25 | 2022 |
| Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinomaEpigenetic modification of immune response in ovarian HGSC P Spiliopoulou, S Spear, H Mirza, I Garner, L McGarry, F Grundland Freile, ... Molecular Cancer Therapeutics, 2022 | 23 | 2022 |
| USP9X controls translation efficiency via deubiquitination of eukaryotic translation initiation factor 4A1 Z Li, Z Cheng, C Raghothama, Z Cui, K Liu, X Li, C Jiang, W Jiang, M Tan, ... Nucleic acids research 46 (2), 823-839, 2018 | 20 | 2018 |
| Efficacy and safety of weekly paclitaxel plus vistusertib vs paclitaxel alone in patients with platinum-resistant ovarian high-grade serous carcinoma: the OCTOPUS multicenter … S Banerjee, G Giannone, AR Clamp, DP Ennis, RM Glasspool, ... JAMA oncology 9 (5), 675-682, 2023 | 9 | 2023 |
| Identification and characterization of isocitrate dehydrogenase 1 (IDH1) as a functional target of marine natural product grincamycin B Z Wang, Z Li, W Zhao, H Huang, J Wang, H Zhang, J Lu, R Wang, W Li, ... Acta Pharmacologica Sinica 42 (5), 801-813, 2021 | 5 | 2021 |
| The genomic trajectory of ovarian high grade serous carcinoma is determined in STIC lesions Z Cheng, DP Ennis, B Lu, HB Mirza, C Sokota, B Kaur, N Singh, ... bioRxiv, 2024.03. 11.584384, 2024 | 1 | 2024 |
| Abstract PR-004: The evolution of ovarian high grade serous carcinoma from STIC lesions Z Cheng, DP Ennis, B Lu, H Mirza, C Sokota, B Kaur, N Singh, O Le Saux, ... Cancer Research 84 (5_Supplement_2), PR-004-PR-004, 2024 | | 2024 |
| The copy number landscape of early stage ovarian high grade serous carcinoma Z Cheng, HB Mirza, DP Ennis, P Smith, LM Gavarró, C Sokota, ... Cancer Research 82 (12_Supplement), 53-53, 2022 | | 2022 |
| 4P Targeting PI3K/AKT/mTOR pathway in platinum-resistant ovarian high-grade serous carcinoma: Translational analysis from the randomized phase II OCTOPUS trial G Giannone, D Ennis, HB Mirza, Z Cheng, J McDermott, LA Lewsley, ... Annals of Oncology 33, S384, 2022 | | 2022 |
| A Randomised, Multi-centre Phase II Trial of Weekly Paclitaxel and Vistusertib in Platinum-Resistant Ovarian High-Grade Serous Carcinoma: OCTOPUS Arm 1 S Banerjee, G Giannone, A Clamp, D Ennis, R Glasspool, R Herbertson, ... medRxiv, 2022.05. 26.22275618, 2022 | | 2022 |
Iain McNeishProfessor of Oncology, Department of Surgery and Cancer, Imperial College LondonVerified email at imperial.ac.uk
